Partial Splenic Embolization for Portal Hypertension Exacerbation During Atezolizumab/Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma
In Vivo · 2025
DOI: 10.21873/invivo.13898 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2025. Verfasst von Toru Ishikawa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan; toruishi@ngt.saiseikai.or.jp. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Embolization, Therapeutic, Hypertension, Portal. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan; toruishi@ngt.saiseikai.or.jp.
- Department of Radiology, Saiseikai Niigata Hospital, Niigata, Japan.
- Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
Zitieren
APA
Ishikawa, T., Terai, N., Sato, R., Natsui, H., Iwasawa, T., Ogawa, M., Kobayashi, Y., Sato, T., Yokoyama, J., Iiduka, A., & Honma, T. (2025). Partial Splenic Embolization for Portal Hypertension Exacerbation During Atezolizumab/Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma. In Vivo. https://doi.org/10.21873/invivo.13898
Vancouver
Ishikawa T, Terai N, Sato R, Natsui H, Iwasawa T, Ogawa M, et al. Partial Splenic Embolization for Portal Hypertension Exacerbation During Atezolizumab/Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma. In Vivo. 2025. doi:10.21873/invivo.13898
BibTeX
@article{Ishikawa2025,
author = {Ishikawa, Toru and Terai, Nanako and Sato, Ryo and Natsui, Hiroki and Iwasawa, Takahiro and Ogawa, Masahiro and Kobayashi, Yuji and Sato, Toshifumi and Yokoyama, Junji and Iiduka, Akihiko and Honma, Terasu},
title = {Partial Splenic Embolization for Portal Hypertension Exacerbation During Atezolizumab/Bevacizumab Combination Therapy in Unresectable Hepatocellular Carcinoma},
journal = {In Vivo},
year = {2025},
doi = {10.21873/invivo.13898}
}
EUVIMED